Internal Medicine

There is a high association between parents' concerns of autism spectrum disorder in their children and identified symptoms of ADHD.

Both monotherapy and combination of the unique regimen was shown to improve manic and depressive status at 12 weeks.

The indication is the first of its kind for the rare, sometimes quickly fatal disease.

Results of a phase 3b trial suggest testosterone treatment could prevent the development of diabetes in men with low serum testosterone levels.

The SOLOIST-WHF trial indicates that SGLT2 inhibition may lead to an overall reduction in cardiovascular-related deaths and hospitalizations.

Primate model studies show the procedure can be done safely and without losing eye function. Which patients may benefit first?

A new study finds benefit to hemoglobin A1c reductions made following conception.

A conversation on how associations between the chronic conditions have become better understood in 10 years.

Primary care physicians should be aware of which patients are at high risk for developing glaucoma.

Only Nebraska and Vermont saw a decrease in NAS rates between 2010-2017.

The current literature points to the potential efficacy and safety of the anti-depressant drug, but more research is needed to verify its role in managing pain caused by vaso-occlusive crises.

The study finds that individuals with mothers who had pregestational diabetes had a 2.3-fold increased risk of MS compared to those with non-diabetic mothers.

Obese or overweight men participating in a lifestyle-based program had lower rates of diabetes after 2 years when also given testosterone therapy, a new study finds.

The negative effects of the pandemic may disrupt efforts to eradicate HBV as a public health threat by 2030.

Alnylam plans to submit a NDA for the orphan drug used to treat hATTR with amyloidosis in adults.

A discussion around obesity's effect on asthma, and the newest recommendations for managed care.

Peter Lio, MD talks about the promise and risks of cannabinoids as potential treatment for itch.

If approved, the treatment would be the first SGLT2 inhibitor for patients with chronic kidney disease.

Peter Lio, MD, discusses a few surprising therapies for pruritus that show some promise.

Few studies have used semiobjective tests to assess olfactory dysfunction and its association with COVID-19.

A seven-question quiz comparing the respiratory viruses. Can you pass it?

New phase 3 data show the IL-23 inhibitor is associated with clinical remission and endoscopic response.

The US Assistant Secretary for Health offers perspective on this past year in sickle cell care and the potential for its future.

Further investigation needs to be done to determine whether this increase is due to the effects of lockdowns or the virus itself.

The burden of cardiovascular disease is particularly high in African Americans, a population that typically faces health disparities.